Brawn Biotech Limited has announced the resignation of Director Mrs. Braj Bala Gupta from the company's Board of Directors, effective November 25, 2025. The pharmaceutical company communicated this development to BSE Limited on December 22, 2025, in compliance with regulatory requirements.

Resignation Details

The resignation was formally submitted through a letter dated November 25, 2025, addressed to the Board of Directors. Mrs. Gupta's departure follows her decision to step down due to personal and professional commitments that prevent her from continuing in her directorial role.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III Part A Para 7C. The company also referenced details under SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, ensuring full compliance with disclosure requirements.

In accordance with SEBI circular dated July 13, 2023, Brawn Biotech Limited provided comprehensive details regarding the resignation. The company confirmed that Mrs. Gupta was not a member of any board committees prior to her resignation, which simplifies the transition process.

Director's Confirmation

Mrs. Braj Bala Gupta provided written confirmation to the company stating that there are no other material reasons for her resignation beyond those mentioned in her resignation letter. This confirmation addresses regulatory requirements for transparency in directorial changes and ensures stakeholders have complete information about the circumstances surrounding her departure.

The resignation letter expressed gratitude to the Board, management, and all stakeholders for the support extended during her tenure as Director. Company Secretary and Compliance Officer Priyanka Sharma handled the formal communication to BSE Limited regarding this corporate announcement.

Company Information

Brawn Biotech Limited operates in the pharmaceutical sector with its registered office located at C-64, Lajpat Nagar-1, First Floor, New Delhi-110024. The company's manufacturing facility is situated at Plot No. 44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram-122001, Haryana. The company trades on BSE under scrip code 530207 with the symbol BRAWN.

Brawn Biotech Limited , a pharmaceutical company, has announced its financial results for the second quarter ended September 30, 2025. The company reported a net loss of Rs. 7.44 lacs for the quarter, with revenue from operations standing at Rs. 797.00 lacs.

Key Financial Highlights

Financial Performance Analysis

Brawn Biotech's revenue from operations showed a significant improvement compared to both the previous quarter and the same quarter last year. However, despite the increase in revenue, the company reported a net loss for the quarter.

Operational Highlights

• The Board of Directors approved the unaudited financial results in their meeting held on November 14, 2025.
• The company's total expenses for the quarter stood at Rs. 798.98 lacs, showing an increase from the previous quarter.
• Other income for the quarter was Rs. 9.12 lacs, remaining relatively stable compared to the previous quarter.

Balance Sheet Overview

As of September 30, 2025, Brawn Biotech reported:

• Total assets of Rs. 2,215.67 lacs
• Total equity of Rs. 370.52 lacs
• Current liabilities of Rs. 1,885.15 lacs

Auditor's Review

Rajiv Udai & Associates, Chartered Accountants, conducted a limited review of the financial results. They stated that nothing has come to their attention that causes them to believe that the financial results do not present a true and fair view in accordance with applicable accounting standards and other recognized accounting practices and policies.

Investors and stakeholders are advised to consider these results in the context of overall market conditions and the pharmaceutical industry's performance.